Last reviewed · How we verify

GSK Biologicals' HPV vaccine 580299

GlaxoSmithKline · FDA-approved active Biologic Quality 5/100

GSK Biologicals' HPV vaccine 580299 is a Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved. Also known as: Cervarix.

At a glance

Generic nameGSK Biologicals' HPV vaccine 580299
Also known asCervarix
SponsorGlaxoSmithKline
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK Biologicals' HPV vaccine 580299

What is GSK Biologicals' HPV vaccine 580299?

GSK Biologicals' HPV vaccine 580299 is a Biologic drug developed by GlaxoSmithKline.

Who makes GSK Biologicals' HPV vaccine 580299?

GSK Biologicals' HPV vaccine 580299 is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is GSK Biologicals' HPV vaccine 580299 also known as anything else?

GSK Biologicals' HPV vaccine 580299 is also known as Cervarix.

What development phase is GSK Biologicals' HPV vaccine 580299 in?

GSK Biologicals' HPV vaccine 580299 is FDA-approved (marketed).

Related